Luna DNA is the first and only genomic and medical research knowledge base powered by the blockchain and owned by its community. SAN DIEGO, Dec. 18, 2017 /PRNewswire/ — Luna DNA, the first and only genomic and medical research knowledge base powered by the blockchain and owned by its community, announced $2 Million in Seed funding today. The round included... Read more
CONTACT: Steve Quinlan, Vice President & CFO, 517/372-9200 LANSING, Mich., Dec. 8, 2017 — Neogen Corporation (NASDAQ: NEOG) today announced that its Board of Directors has approved a four-for-three stock split. With the split, shareholders of record on Dec. 18, 2017, will receive one additional share of stock for each three shares held. The stock split... Read more
New members of the Executive Board of the ZEISS Group Effective 1 January 2018, Dr. Karl Lamprecht for the Semiconductor Manufacturing Technology segment and Dr. Jochen Peter for the Research & Quality Technology segment have been appointed to the Executive Board of the ZEISS Group Thomas Spitzenpfeil, Member of the Executive Board, to pursue new... Read more
Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia This chemotherapy-free combination showed improvements across multiple efficacy measures compared to bendamustine plus MabThera/Rituxan in the pivotal MURANO trial... Read more
Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia This chemotherapy-free combination showed improvements across multiple efficacy measures compared to bendamustine plus MabThera/Rituxan in the pivotal MURANO trial... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced Aimee Hoyt, an accomplished and strategic talent leader, will head its human resources team. Ms. Hoyt will join as Senior Vice President and Chief People Officer (CPO), starting January 8, 2018, and will be responsible for leading all aspects of the company’s HR strategies, reporting to the CEO. “After... Read more
Basel, 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer Tecentriq and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1 Data will... Read more
Basel, 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer Tecentriq and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1 Data will... Read more
Basel, 10 December 2017 Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma Polatuzumab vedotin combination demonstrated improvements across multiple efficacy measures compared to BR alone in relapsed or refractory diffuse large B-cell lymphoma These data led to... Read more
Germantown, Maryland, and Hilden, Germany, December 08, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it is transferring the U.S. listing of its global shares to the New York Stock Exchange (NYSE) from the NASDAQ Global Market. The transfer to the NYSE is expected to be effective on or about January... Read more